the pharmacology of glaucoma: not just iop, think dpp, omg! · 2019-02-10 · i’m a clinician, so...
TRANSCRIPT
The Pharmacology of Glaucoma: NOT
just IOP, Think DPP, OMG!
Bruce E. Onofrey, OD, RPh, FAAO
Professor, Univ. Houston
Exec. Director Continuing Education Programs
EVIDENCE BASED MEDICINE
• Rational care requires a scientific
approach to patient management
• Sound clinical research should be
the basis for therapeutic decisions
• Know the Disease: Pathophysiology
• Know the patient: Histories
• Know the therapy: Pharmacology
The impact of clinical research on
current glaucoma management
• Who we treat and who we watch
• Initial drug selection/ maximizing drug combinations / max medical therapy
• How we (most accurately) assess disease progression
• The relationship between IOP and BP in GLC patients
• Evaluating and resolving similar studies with differing outcomes (sponsor bias?)
I’m a clinician, so let’s talk patients
TWO Patients ( a priest and a lawyer) with
the same med HX walk into a bar
• 54 Y/O WT M presents for general exam/DM eye evaluation
• FM HX DM, HTN
• FM EYE HX-NEG
• Patient Med HX:
Type II DM X 5 Yrs-A1-C = 7
BP controlled with TX = 125/65
Lipitor for elevated lipids
• No allergies
Significant eye findings
• IOP’s: 26/24@
9AM
• C/D: 0.5/0.5 OU
• VF: 30-2
NML VF’s & Discs c elevated
IOP’s……TX??
Hold the thought
What is glaucoma?
Just one of many types of
Anterior Optic Neuropathy
Definition does not mention IOP-
IS IOP IMPORTANT?
“TOM” says that it is
The OHT Study - Goals
Evaluate the safety and efficacy of using topical ocular hypotensive medication(s) in preventing or delaying the development of POAG in individuals with elevated IOP
Identify baseline demographic and clinical factors that predict which individuals would develop POAG
OHTS – Study Design
•Patients randomly assigned to one of two
groups
–Treatment or Close Observation
–Treatment goal to lower IOP at least
20%
•Management
–Humphrey VF 30-2 every 6 months
–Annual dilated exam & photos
OHTS Population
Entry Criteria
–Age 40 – 80
–Normal visual fields
• Humphrey 30-2 FT
–Normal optic discs
–Untreated IOP
• 24 to 32 mm Hg in
qualifying eye
• 21 to 32 mm Hg in
fellow eye
OHTS demographics
–Enrollment complete
in 10/96
–Last patient 5 yr. data
11/8/01
–1,636 subjects at 23
clinical centers
–1,408 completed 5 yrs.
–409 (25%) Africian
American
OHTS Study Design• 1,636 individuals randomized to Therapy (817)
or Observation (819)
• Minimum life of study – 5 years
– 7 years follow-up for some patients
–Some individuals dropped out, medication
started or withdrawn, died, or lost to
follow-up
• 1,408 completed study
–Observation (706) vs. Therapy (702)
Facts, Fiction and Statistics
KNOW YOUR OHT’s (N = 1636)
• Early TX of ocular hypertension reduced
the risk of glaucoma by FIFTY
PERCENT
• 9.5% VS 4.4%
• That means that over 90% of
UNTREATED ocular hypertensives DO
NOT GET GLAUCOMA
• Know your NNT-Number needed to TX
• Need to TX 20-42 to prevent 1 case of glc
POAG Endpoints by Central Corneal Thickness
and Baseline IOP (mmHg) in Observation Group*
Baseline IOP (mmHg)
Central Corneal Thickness (microns)
* through 8 Nov 2001
< 23.75
>23.75 to < 25.75
>25.75
< 555 >555 to < 588 >588
17% 9% 2%
12% 10% 7%
36% 13% 6%
Vertical C/D Ratio
Central Corneal Thickness (microns)
* through 8 Nov 2001
< 0.30
>0.30 to <0.50
>0.50
< 555 >555 to < 588 >588
15% 1% 4%
26% 16% 4%
22% 16% 8%
POAG Endpoints by Central Corneal Thickness
and Baseline Vertical C/D Ratio in Observation Group*
The OHTS Lesson
• Treating all ocular hypertensives is not safe/effective or cost effective
• Pachymetry is important
• Conversion best determined by Optic Nerve (Nerve fiber layer) changes HOLD THAT THOUGHT
• TX is optional if risk is acceptable
• IF NFL changes or disc changes TX-DON’T wait for VF changes (thank Harry Quigley again)
Assessment
• Tonometry
• Optic nerve evaluation
• Visual fields
• Pachymetry
• NFL analysis
Optic Disc Hemorrhage
(Drance Hemorrhage)
• Usually Superficial In NFL
• Present On Or Adjacent To The Disc
• 70% Located Infra-temporally
• Resolve In One To Three Months
• Often Recurrent
Optic Disc Hemorrhage
(Drance Hemorrhage)
• Occurs In 2-23% Of Glaucoma Patients
• More Frequent - Normal Tension Than
High Tension Glaucoma
• Indicator Of Early Or Progressive Nerve
Damage
• May Precede Optic Nerve And Visual Field
Changes
• Warrants Re-evaluation Of Current
Treatment
EMGT-Early Manifest Glc Trial ( NEI and
Swedish Res. Council-Anders Hiejl 2002)
• 6 year study of TX VS non-TX of early glc
patients with IOP</= 30 and minimal VF defect
N = 255 TX: Betaxolol and ALT-AVG 25%
drop in IOP
• TX lowered risk of progression by 10%/mm
drop in IOP-
• TX lowered early damage seen in control group
• Risk increased with higher IOP, greater field
defects, exfoliation and recurrent disc heme
• First sign of progression VF-86%, Disc change
1%, Both 13% / NNT = 6
Progression of all patients
N at
risk:
T: 68
C: 64
67
61
63
53
54
43
45
37
30
22
17
13
8
6
3
0
N at
risk:
T: 61
C: 62
55
52
48
40
43
29
37
24
21
14
10
9
6
5
2
3
N at
risk:
T: 8
C: 15
7
11
6
7
5
3
3
3
2
0
0
0
N at
risk:
T: 121
C: 111
115
102
105
86
92
69
79
58
49
36
27
22
14
11
5
3
IOP <21 mmHg IOP ≥21 mmHg
Exfoliation No exfoliation
N at
risk:
T: 69
C: 77
67
74
64
62
57
48
50
40
29
25
15
15
8
9
3
3
N at
risk:
T: 60
C: 49
55
39
47
31
40
24
32
21
22
11
12
7
6
2
2
0
N at
risk:
T: 63
C: 57
60
53
55
48
49
40
42
33
29
22
14
12
8
8
3
1
N at
risk:
T: 66
C: 69
62
60
56
45
48
32
40
28
22
14
13
10
6
3
2
2
MD better than -4.5 dB MD worse than -4.5 dB
Age <68 years Age ≥68 years
1. EVERY 1 MM DROP IN IOP = 10% REDUCED
RISK OF PROGRESSION
2. VF’S ARE THE BEST PREDICTOR OF
GLAUCOMA PROGRESSION IN PATIENTS
WITH DX’D GLC
3. TX INCREASED RISK OF CATARACT
4. DISC (DRANCE) HEMMORRHAGES
PREDICT PROGRESSION
EMGT (fast) Conclusions
EMGT: Take Home Messages
• Reducing IOP 25% (about 5 mmHg)
prevents the progression of early
glaucomatous defects – halves the risk!
• Study about white Swedes with
moderately elevated IOPs
• Observations regarding progression in
lenticular opacification requires further
study
The real story of OHTS VS
EMGT (thanks Harry Quigley)
• ON reserve VS ON decompensation
• Don’t wait for VF loss to TX Ocular
Hypertensives=save the reserve-monitor disc/NFL with OCT/GDX
• VF’s very sensitive in patient’s that have lost their reserve NFL
• Depend heavily on VF’s in dependable VF takers with pre-existing field loss
Lower IOP Stabilizes Glaucoma Progression
% of
Patients
100%
0%
20%
40%
60%
80%
12/13 14/15 16/17 18/19 20/21 22/23
Intraocular Pressure (mm Hg)
Glaucoma Stable Glaucoma Progressing
Additional Support (AGIS):“The AGIS data support the suggestive evidence from earlier studies
that achieving low levels of intraocular pressure slows the progression
of glaucomatous optic neuropathy”
Adapted from: Mao LK, et al. Am J Ophthalmol 1991;111:51-55.
(AGIS):7 Amer Jrl Ophthalmol 2000;130(4):429-440
Maximize patients with IOP 17
ASRANI: Get it low AND KEEP IT LOW ALL DAY
Low IOP during office hours is important, but 24 hour
control is the key-Asrani study demonstrates
importance of a flat diurnal curve
• Method:
• 64 patients (105 eyes)
• Self tonometry 5X / day X 5 days = 25 readings per patient
• Avg range 10 +/- 2.9mm Hg
• Risk of progression directly related to degree of fluctuation
• Caprioli AGIS data confirms importance of dirunal fluctuation as an independent risk factor
Low Pressures Should Be Maintained Over
24 Hours
12
43
57
88
0
10
20
30
40
50
60
70
80
90
100
Highest
Diurnal IOP
Fluctuation
Lowest
Diurnal IOP
Fluctuation
Risk Associated With Diurnal IOP Variations
Asrani S, et al.. J Glaucoma. 2000;9(2):134–142.
Stable Vision Loss
DIURNAL CHANGE
IS IMPORTANT
The IOP in
Glaucoma Fluctuates
More Than You
Think
Normal IOP Does Not Exclude
Glaucoma
• The Baltimore Eye Survey:
• Up to 50% of the Patients Diagnosed With Glaucoma
(Based on Optic Nerve and VF) Had an Initial IOP
Reading Below 21Mm Hg
• Tonometry Is Not a Glaucoma Test
• Glaucoma Testing Is a Complete Eye Exam
• If You Are Not Diagnosing Glaucoma in Patients With
Normal IOP, Then You Are Missing Cases of
Glaucoma
• Lowering IOP is Beneficial for Patients with NTG
• Collaborative
NTG
Treatment
Trial– CNTG Group. Am J
Ophthalmol.
1998;126:487-497
– 30% IOP
reduction limits
VF progression
by 2/3
@@@@@@
– 140 eyes
0
0.2
0.4
0.6
0.8
1
1 2 3 4 5 6 7 8
Proportion
of patients
with
protocol-
defined
endpoints
Years
Treated
Controls
P <
0.0001
Beware of Pseudo NTG:
Diurnal fluctuation
Thin corneas
These studies indicate the need for at least three Baseline
IOP Readings Before Starting Glaucoma Treatment
• Helps Uncover Diurnal Fluctuation
• Mix Two Morning Readings With One Afternoon
• Imperative for Setting Target Pressures
• Emphasize the Highest Reading when Setting the
Target Pressure
• Allows for Determining the Effectivity of
Medications
• A Diurnal study is imperative for NTG suspects
• Pachymetry is now standard of care
LALES Study
C/D Ratio as screening tool
• Los Angeles Latino Eye Study
• Comprehensive evaluation for predictors
of eye disease in this population
• 6,357 latinos over 40Y/O
• Vertical C/D > 0.6 cutoff for glc screening
• 92.3% sensitive for glc
• 95.3% specificity for glc
The 3-A’s of Glaucoma
Management
• A- Assessment
• A- Action
• A- Adios
Treatment goals
• Minimum 20%
• Below 18mm hg
• Minimize diurnal variation
KWIK KWIZ
• 67 Y/O AA female
• (+) Type II DM X 20 yrs
• (+) Systemic hypertension
• (+) 2nd degree heart block
• (+) atrial fibrilation
• (+) Hyperlipidemia
• (+) On renal transplant list – on dialysis
• (+) Lupus
• (+) Asthma
MED HX: ContinuedDRUGS ALLERGIES
• Lisinopril Thiazide Diuretics
• Lipitor Glyburide
• Amiodarone Clonidine
• Digoxin
• Insulin
• Steroid inhaler/oral pred as needed
• Frequent HX of hypoglycemic events
Eye findings• BVA: OD 20/20
OS 20/50
• Pupils: 3mm (+) 3RX OU
(-) APD
SLE: OU: NML
IOP: OD 26 OS 29
Gonios: TM visible in 2 quadrants OD and 3 OS
Pachymetry: 505/498
Discs: H/V
OD: 0.6/0.9
OS: 0.8/0.9
Drug Class Mechanism of Action
Cholinergic agonists
2-Adrenergic agonists
2-Adrenergic antagonists
2-Adrenergic agonists
Carbonic anhydrase
inhibitors
Prostaglandin F2
derivatives
Ciliary muscle contraction (facilitating
uveoscleral outflow and trabecular outflow)
Inhibition of aqueous production
by the ciliary epithelium
Inhibition of aqueous production
by the ciliary epithelium ± increasing
uveoscleral outflow
Increased uveoscleral outflow
Increasing trabecular outflow by a
mechanism that is not completely
understood
Inhibition of aqueous production
by the ciliary epithelium
Available Treatments
When combining drugs-go for
synergism
• Reduced Aqueous
• Beta-blockers
• Alphagan
• Propine/epi
• Azopt/Trusopt/
Diamox
• Increased outflow
• Pilo
• Prostaglandins
• Propine/epi
Ocular Beta-Blockers
30 years of experience
Known efficacy
Known contraindications
Name 8 potentially fatal Beta-
blocker Adverse Effects
• Adverse Effects
1. Asthma
2. Coronary insufficiency
3. Heart block/arrhythmia
4. Depression
5. Diabetics
6. Anaphylaxis reversal
7. Lipid abnormality in coronary artery disease
8. Impotence (just feel like you want to die)
Are You Short of
Breath?@@@@@ • Peak flow testing is
“IN”-standard of care-
ONLY objective test of
lung function
• Check pulse and BP
• AVOID B-BLOCKERS
AND THE LAWYERS
WILL HATE YOU
Is it safe to use beta blocker
topicals and orals together?
• MAYBE
• Probably NOT a good idea
• LOWER EFFICACY-HIGHER SIDE-
EFFECTS
• AVOID BETA-BLOCKERS at NIGHT,
lower efficacy, reduced
perfusion@@@@@
On-going patient evaluation is
critical
• 10% of patients have obvious
contraindications to beta-blockers
• 12% of “normals” will develop
significant side-effects that will require
discontinuation of TX
• Good VS Bad side-effects
Avoid beta-blockers at night?
• @@@@@@@@@@@@
• Reduction of aqueous production during
sleep
• Drop in BP during sleep
• Beta blockers reduce perfusion pressure
by vasodilation and decreased cardiac
output
• Increased risk of nocturnal hypotensive
event
Topical CAI’s -Wonder Drug
or Wonder DUD
-Trusopt-
• WHEN it works it works
real good: Equivalent to
BB: 15-25%
• When it fails it fails real
bad
• Poor for monotherapy
• Great with…..
• Note: they are sulfonamides
• The same/but different
Alphagan-Alpha-2 specificity
makes for a better drug• Alpha-2 Specific
• No tachyphylaxis
• Reduced allergy
• BID dosage if in combination-
TID is more appropriate if
used alone(diurnal drift)
• Beta blocker equivalent
• Good choice for pulmonary
compromised patients
• Neuro-protective? Not in
humans yet
• Perfusion pressure
Sympathomimetics
• Epinephrine/Propine
• No efficacy
• Red eyes
• Contraindicated in:
• High BP
Heart disease
Migraine patients
A DEAD
(OBSOLETE)
DRUG
Prostaglandin Derivatives
QUESTION #1:Should prostaglandins be
used as first line therapy
• 1. Incredible efficacy
• 2. Minimal systemic side-effects
• 3. Minimal diurnal fluctuation
• 4. Minimal tachyphylaxis
• DUHHHHHHHHHHH
Source: Bateman 2002, Walt 2002
Use of newer, more expensive glaucoma agents
increased, while surgeries decreased
Glaucoma Surgery Trend 1994-1999
25%
-48% -46%
-50%
-40%
-30%
-20%
-10%
0%
10%
20%
30%
New Rx Products Older Products Surgical
Interventions
The “NEW” Prostaglandin
Latanoprostene bunod 0.024%
• MOA:
• 1. Increase in extra-trabecular outflow
• 2. Bunod component donates nitric oxide which
produces increased trabecular outflow
•
JUPITER STUDY-Phase 1
• Single arm study with 130 POAG/OHTN
Japanese patients
• Range of IOP = 15 – 30 mmHg
• Avg drop in IOP from 19.6mm down to
14.4 mmHg = 26.5%
VOYAGER Phase 2
• Latanoprostene vs Latanoprost
• Compared latanoprost 0.005% = -7.77mmHg
• LBN: 0.006% = -7.81mmHg
• 0.012% = - 8.26 mmHg
• 0.024% = - 9.00 mmHg
• 0.040% = - 8.93 mmHg
• On avg: 1-1.5mm lower IOP = 29.8% vs 34.6%
• Hyperemia:
• LBN 7% Latanoprost 8.5%
• Cost: 5ml : $366- $392
• Netarsudil 0.02%
• Rho-Kinase Inhibitor
• Inhibits both the enzyme rho-kinase and
norepinephrine transporter = increased
adrenergic activity
• MOA:
• 1. Increased trabecular outflow
• 2. Decreased episcleral venous pressure
• 3. Decreased aqueous production
Drug delivery
• Contact lenses
• Punctal Plugs
• Insertable
• Injectables
On the horizon: New topical ocular drug
delivery systems
Mystic Pharmaceuticals “nautilus” unit dose non-
preserved microspray or drop
dispenser-5-30uL adjustable
Eyenovia: Electrostatic “pixel”
size spray: Piezo-electrically
“prints” 6uL dose onto surface of
eye vs 50uL drop
Ocular Therapeutix:
Dextenza: Reabsorbable
dexamethasone releasing
lacrimal insert –Phase III , failed
to reduce itching in allergic
conjunctivitis-97% retained after
30 days- no IOP spikes?
Neuroprotection: Currently
NONE, but in the Future
• Block excitotoxins: Produce cellular
damage after ischemia or stress
• Glutamate
• Aspartate
• N methyl-d-aspartate (NMDA)
• Calcium channel blockade
Treatable Risk Factors For Glaucoma
Progression And Their Relationship To
Adjunctive Medications
• Treatable
- Intraocular pressure (IOP)
• Elevated IOP
• Variation in IOP
– 24 hours (diurnal and nocturnal)
- Ocular Perfusion Pressure
American Academy of Ophthalmology. Primary Open-Angle Glaucoma Suspect, Preferred Practice Pattern. San Francisco:
American Academy of Ophthalmology, 2005. Available at: www.aao.org/ppp.
Low ocular perfusion pressure has been shown to be strongly associated with the prevalence of glaucoma progression in multiple population-based surveys
Tielsch JM, et al. Arch Ophthalmol. 1995.
Leske MC, et al. Arch Ophthalmol. 1995.
Leske MC, et al. Arch Ophthalmol. 2002.
Quigley HA, et al. Arch Ophthalmol. 2001.
Bonomi L, et al. Ophthalmol. 2000.
Leske et al.Ophthalmology 114 (11), November 2007
BP – IOP = Ocular Perfusion Pressure (OPP)(BP is mean arterial pressure, diastolic BP, or systolic BP)
Ocular Perfusion Pressure
and Glaucoma Progression
Perfusion Pressures
• Mean arterial pressure (MAP) = 2/3
diastolic + ½ systolic
• Mean Arterial OPP = MAP- IOP
• Systolic OPP = Systolic - IOP
• Diastolic OPP = Diastolic - IOP
Lower Diastolic,
Systolic, or
Mean Pressure
Reduces Perfusion
Pressure
Higher
IOP
Negatively Impacts
Perfusion Pressure
Perfusion Pressure
Is a Result of
A Delicate Balance
Between IOP
and Blood Pressure
Lower
Perfusion Pressure
Is Associated with
Increased Risk for
Open Angle GlaucomaLeske MC, et al. Ophthalmology 2007; 114,: 1965-72
Leske MC, et al. Ophthalmology 2008;115, 65-93.
Hayreh SS. Trans Am Acad Ophthalmol 1974;78:240-54
Ocular Perfusion Pressure and Glaucoma
Progression
OPP and Glaucoma Progression:
Population Studies
• Baltimore Eye Survey (AA and Caucasian)1
- 6x excess of POAG in subjects with lowest category of Ocular Perfusion Pressure (OPP)
• Egna-Numarkt Study (Caucasian)2
- Lower Diastolic Ocular Perfusion Pressure (DOPP) associated with marked, progressive increase in frequency of POAG
• Barbados 4 yr Eye Study (African-Caribbean)3
- 4-year risk of developing glaucoma increased dramatically at lower perfusion pressure
• Proyecto Ver (Hispanic)4
- Found lower Diastolic Perfusion Pressure (DPP) associated with increased risk of POAG
1. Tielsch, Katz, Sommer, Quigley, Javitt. Arch Ophthalmol 1995;113:216-21
2. Bonomi L, Marchini G, Marraffa M et al. Ophthalmology 2000;107:1287-93
3. Leske MC, Wu S-Y, Nemesure B, et al. Arch Ophthalmol 2002;120:954-9.
4. Quigley HA, West SK, Rodriguez J, et al. Arch Ophthalmol. 2001;119:1819-26.
Ocular Perfusion Pressure
and Glaucoma Progression: New
Evidence
• Barbados Eye Study 9-year Risk
Factor Study
• EMGT Predictors for Long-term
Progression
• Thessaloniki Eye Study
• EGPS Inter-current Risk Factors
OPP: Barbados 9-year
• Cohort study of African-Caribbeans
residing in Barbados, West Indies
• 9-year risk of developing glaucoma
increased dramatically at lower
perfusion pressure
Leske MC, Wu S-Y, Nemesure B, et al. Arch Ophthalmol 2002;120:954-9.
POAG Risk Factors 9-year
BES
Leske MC, Wu S-Y, Nemesure B, et al. Ophthalmol 2008;115:85-93.
Barbados Eye Study
Conclusions
• Correlates indicating increased risk of
GLC progression (in order of significance)
Low mean perfusion pressure
Family HX of GLC
Corneal thickness
Elevated IOP
Age
Increased Systolic BP was a protective
Thessaloniki Eye Study
• Performed HRT in 263 subjects
• Excluded those subsequently identified with
glaucoma
• Patients with DBP < 90 as a result of
systemic anti-HTN treatment had larger C:D
ratios and cup areas on HRT compared to
normals with DBP < 90 and HTN patients with
BP ≥ 90
Topouzis et al. Am J Opthalmol 2006;142:60-67
FINALLY, how does perfusion
pressure data effect drug
selection and treatment
methods?• What’s happening to IOP at night?
• What drugs work well on a 24 hour?
cycle (particularly during sleep)?
• Which drugs maximize 24 hour IOP
control with minimal effect on BP?
• First, the LIU studies from Weinrebs
GLC lab
Both healthy eyes and eyes with glaucomatous changes showed
higher nocturnal supine IOP than diurnal sitting IOP
Supine IOP is higher than sitting IOP, regardless of time of day
Healthy supine IOP
Healthy habitual IOP
IOP Is Higher at Night
IOP
(m
m H
g)
Glaucoma supine IOP
Glaucoma habitual IOP
3:3
0 A
M
3:3
0 P
M
5:3
0 P
M
7:3
0P
M
9:3
0 P
M
11
:30
PM
1:3
0 A
M
5:3
0 A
M
7:3
0A
M
9:3
0 A
M
11
:30
AM
1:3
0 P
M
252423222120191817161514
26
Clock Time
n=24
Nocturnal
Supine
Diurnal SittingDiurnal SittingNocturnal
Supine
Diurnal SittingDiurnal Sitting
Clock Time
1:3
0 P
M
IOP
(m
m H
g)
252423222120191817161514
26
3:3
0 A
M
3:3
0 P
M
5:3
0 P
M
7:3
0 P
M
9:3
0 P
M
11
:30
PM
1:3
0 A
M
5:3
0 A
M
7:3
0A
M
9:3
0 A
M
11
:30
AM
n=24
Nocturnal
Supine
Diurnal SupineDiurnal SupineNocturnal
Supine
Diurnal SupineDiurnal Supine
Liu et al. Invest Ophthalmol Vis Sci. 2003;44:1586-1590.
Glaucoma Medications and their effects on
Ocular Perfusion Pressure (OPP)
27 Patients treated with BID timolol 0.5%, BID
brimonidine 0.2%, TID dorzolamide 2% or QHS
latanoprost 0.005% for six weeks, followed by a 4-
week washout period between different
treatments
24-hour IOP monitoring in habitual position
24-hour systemic blood pressure monitoring
Quaranta L et al. Invest Ophthalmol Vis Sci. 2006;47:2917-2923.
GOAL: Based upon drug effect on IOP and BP find the
best mono therapeutic agent and best drug combination
Baseline Timolol Brimonidine Dorzolamide Latanoprost
Mean 24-
Hour IOP
(mm Hg)1
22.69 17.73 18.32 17.37 16.62
1. Quaranta L et al. Invest Ophthalmol Vis Sci. 2006;47:2917-2923.
IOP Results
Baseline Timolol Brimonidine Dorzolamide Latanoprost
Mean 24-
Hour
Diastolic
Ocular
Perfusion
Pressure
(mm Hg)1
50.7 53.0 46.2
Significant
reduction in
DOPP
(p < 0.0001)
55.9
Significant
improvement
in DOPP
(p < 0.0001)
56.4
Significant
improvement
in DOPP vs.
baseline
(p < 0.0001)
1. Quaranta L et al. Invest Ophthalmol Vis Sci. 2006;47:2917-2923.
2. Quigley HA, West SK, Rodriguez J, et al. Arch Ophthalmol. 2001;119:1819-26
Diastolic Ocular Perfusion
Pressure (DOPP) Results
* Reduction in DOPP is a risk factor for glaucoma progression2
Baseline Timolol Brimonidine Dorzolamide Latanoprost
Mean 24-
Hour
Diastolic
Ocular
Perfusion
Pressure
(mm Hg)1
50.7 53.0 46.2
Significant
reduction in
DOPP
(p < 0.0001)
55.9
Significant
improvement
in DOPP
(p < 0.0001)
56.4
Significant
improvement
in DOPP vs.
baseline
(p < 0.0001)
1. Quaranta L et al. Invest Ophthalmol Vis Sci. 2006;47:2917-2923.
2. Quigley HA, West SK, Rodriguez J, et al. Arch Ophthalmol. 2001;119:1819-26
Diastolic Ocular Perfusion
Pressure (DOPP) Results
* Reduction in DOPP is a risk factor for glaucoma progression2
Brimonidine
46.2
Significant
reduction in
DOPP
(p < 0.0001)
Additive effect on IOP of
prostaglandin TX PLUS:
-2
-2.5
-3.9
-5
-4
-3
-2
-1
0
Ch
an
ge i
n I
OP
(m
m
Hg
)
Alpha Agonist Beta-Blockers CAI
Source: Bateman 2002, Walt 2002
Study Conclusions
- PGA and CAI significantly increased
DPP at all time points@@@
- Beta-blocker significantly increased
DPP from 4AM to 4PM but had no effect
at other times
- Alpha agonist significantly reduced DPP
at multiple time points, primarily due to
significant decrease in systemic
BP@@@
Quaranta L, Gandolfo F, Turano R, et al. Invest Ophthalmol Vis Sci 2006; 47: 2917-23.
BEST Combinations
• Prostaglandin (+) Topical CAI
• Avoid Alpha agonist (decreases PP) ie
lowers BP and least effective agent at
night
Relationship between Nocturnal
Hypotension and OPP• Low BP at night, coupled with high IOP in
supine position, compromise OPP
• Use systemic BP meds in the AM to minimize
nocturnal hypotention
• Use IOP lowering drugs that lower IOP during
BOTH the diurnal and nocturnal period (CAI’s
and prostaglandins)
• Avoid IOP meds that lower systemic BP at night
(beta blockers, alpha agonists)Graham, Drance. Surv Ophthalmol. 1999;43(suppl 1):S10-16
Hayreh, Zimmerman, Podhajsky. Am J Ophthalmol. 1994;117:603-624
Colligan, Dewe, Guillaume, Colligan-Brach. Int Ophthalmol 1998;22:19-25
Think holistically
• Consider measuring perfusion
pressures
• Monitor those at greatest risk-low
BP/over-aggressive BP control
• Nocturnal hypotension can produce NA-
ION
• Talk with PCP
REASONS FOR
TREATMENT FAILURE
• Adverse drug effects/
contraindications
• Too many drugs
• Efficacy
• Compliance
Prostaglandins
Compliance sucks